Anticancer antibiotics, anthracyclines, may cause severe left ventricle systolic dysfunction that is associated with poor clinical prognosis. In this review, we discuss the mechanisms and risk factors of anthracycline-induced cardiotoxicity and cardiomyopathy, among which the cumulative administered dose of anthracyclines and concurrent cardiovascular diseases are the most important. We also present strategies for primary and secondary prevention of anthracycline-induced cardiotoxicity via rigorous assessment of early signs of left ventricular dysfunction.
IntRoductIon
The cardiotoxicity of anticancer medications has become a problem of utmost clinical importance. The survival of cancer patients has increased significantly over the past years, which has raised the rate of the delayed cardiotoxic effects of anti-tumor treatment [1] . Patients who have overcome cancer have an increased incidence of cardiovascular complications than their coevals [2] . Cardiotoxic effects of anti-tumor medications lead to the reduction of cumulative anthracycline doses, which may cause tumor under-treatment and poor outcome. Careful cardiologic assessment becomes a cornerstone of optimal management of such patients and should cover risk evaluation of cardiotoxic effects of anticancer drugs, the development of the individualized follow-up programs during and after chemotherapy, and the prevention and management of cancer treatment-induced cardiac dysfunction.
Almost all anticancer drugs may exert negative effects on heart, and the most serious complications include the development of left ventricular systolic dysfunction and heart failure [3] . Systolic dysfunction and heart failure are quite close, but not identical terms. Systolic dysfunction refers to the impairment of cardiac contractility whereas heart failure is a clinical syndrome with its certain symptoms and signs: fatigue, dyspnea, swelling etc.
Systolic dysfunction is a basis of heart failure, though in some cases, systolic dysfunction may be asymptomatic.
The most severe left ventricular systolic dysfunction is caused by antitumor antibiotics -anthracyclines. Systolic dysfunction and heart failure associated with anthracyclines imply anthracycline-induced cardiomyopathy. Systolic dysfunction may also be induced by other anticancer medications (cyclophosphamide, monoclonal antibodies, and tyrosine-kinase inhibitors), but the cardiac dysfunction in anthracycline-induced cardiomyopathy is the most prominent one and has the poorest prognosis.
There are two major types of cancer treatment-related systolic dysfunction based on toxicity mechanisms of the agents used. Anthracycline-induced cardiomyopathy is a prototype of type I ("damage-related") irreversible injury. Type I dysfunction is characterized by myocardial injury that is accompanied by loss of cardiomyocytes and release of markers of cardiac necrosis; the cardiotoxic effect is dose-dependent.
Myocardial damage is generally irreversible; however, early treatment may help in partial recovery of cardiac function.
Even if the recovery of cardiac function is achieved, the re--administration of anthracyclines is contraindicated due to an extremely high probability of the recurrence of very aggressive and refractory cardiomyopathy [4, 5] .
A number of agents do not directly cause cell damage. Trastuzumab-induced cardiac injury (caused by monoclonal antibodies to ErbB2 receptors) is a prototype of type II ("functional") reversible dysfunction. Other agents that can induce type II dysfunction include: tyrosine kinase inhibitors (lapatinib, imatinib, and sunitinib); a kinase inhibitor, sorafenib; monoclonal antibodies (pertuzumab and bevacizumab); a proteasome inhibitor, bortezomib [6] . Type II dysfunction is not associated with cardiomyocyte death or any detectable structural myocardial changes. The risk of cardiac dysfunction is not dose-dependent; the myocardial damage is frequently (albeit not invariably) reversible and vanishes after the drug discontinuation usually within 1-3 months [4] . The re-administration does not usually lead to the recurrence of the left ventricular dysfunction (if readmitted after the recovery of the left ventricular function and with the concomitant cardiac protective treatment). Nevertheless, if cardiomyopathy reoccurs, the anticancer drug should be discontinued.
The distinction of type I and II cardiomyopathy basing on the reversibility of cardiac function is rather schematic, as e.g. small-molecule tyrosine kinase inhibitors induce cardiac dysfunction which shares properties of both types. The clarification of mechanisms behind cardiotoxicity of anticancer agent is further complicated by the fact that type I and type II agents are often given sequentially and concurrently. Such sequential and concurrent use may increase cell death indirectly by compromising the environment of marginally compensated cells, contributing to the concern that type II agents can still result in cell death at the time of administration [7] .
AnthRAcyclInE-InducEd cARdIAc cEll dAmAgE And dEvElopmEnt of cARdIomyopAthy
Anthracyclines result in direct cardiomyocyte loss via apoptosis, diminished contractility, and compromised microvasculature affecting endothelial cells. Furthermore, the effect of anthracyclines on cardiac progenitor cells and fibroblasts reduces the ability of the already compromised heart to recover from additional cardiac stressors or cardiac injuries [8] .
The intracellular interaction of anthracyclines with topoisomerase 2β leads to DNA damage and impairment of mitochondrial function. Generation of reactive oxygen species (ROS) in re-sponse to anthracycline treatment initiate free radical oxidation cascade reactions that affect proteins, lipids and nucleic acids with subsequent cell dysfunction and loss [9] . The diminished expression of the proteins of intracellular calcium-signaling cycle (SERCA2 and Na + /Ca 2+ exchanger) due to ROS as well as the anthracycline-induced disruption of normal sarcomere structure and function both result in decreased myocardial contractility. ROS generation in mitochondria takes part in caspase cascade activation via cytochrome C release.
The underlying structural and functional processes of anthracycline-induced cardiomyopathy are the enlargement of the heart and the decrease of ventricular contractility that manifest as heart failure. The initial decrease of the left ventricular contractility can be revealed as early as 2 hours after the first dose of anthracycline [10] . Nevertheless, cardiomyopathy usually occurs after a year or more of the chemotherapy. The delayed extension of cardiomyopathy may be explained partly by the reserve capacity of the heart to increase the contractility of non-injured myocardium (compensatory hyperkinesis) to maintain the normal contractility of ventricles. However, each dose of anthracyclines causes subsequent loss of a new portion of cardiomyocytes, thus depleting the compensatory capacities of the heart, especially when concomitant cardiac diseases exist.
Recent studies revealed several sequences of the extension and evolution of anthracycline-induced cardiomyopathy. In the vast majority of cases cardiac toxicity occurs within the first year after the chemotherapy [11] . Cardiac dysfunction progresses slowly, and the later it develops, the more aggressive it becomes [12, 13] . Anthracycline-induced cardiac toxicity may occur during the ongoing chemotherapy, but unlike chronic cardiomyopathy, the acute one has favorable clinical outcome and is usually manifested with arrhythmias, non-specific ST and T-wave abnormalities, asymptomatic decrease in left ventricular ejection fraction or pericardial effusion. Acute cardiac toxicity is not dose-dependent and does not usually progress to heart failure. The term "anthracycline-induced cardiomyopathy" describes an irreversible and progressive delayed heart damage due to and following chemotherapy. Anthracycline-induced cardiomyopathy is the most aggressive type of cardiomyopathies: 2-year mortality rate exceeds 50%, which is worse than the poorest prognosis for the primary disease [5] .
RIsK fActoRs of AnthRAcyclInE--InducEd cARdIomyopAthy anthracycline and trastuzumab is associated with the incidence of severe heart failure of 16%, while a 3-month delay in trastuzumab treatment almost eliminates this risk [7] . The concentration of ErbB2 receptors on the surface of cardiac cells returns to baseline values within 2-3 months after cessation of treatment with anthracycline. Hence, the longer the interval between anthracycline and trastuzumab, the lower the risk of heart failure. The most available, cost-effective and safe method for the evaluation of LVEF is echocardiography; however, such limitations as intra-operator or inter-operator variability affect its accuracy.
The 10%-variance in LVEF estimated with echo examination is considered acceptable. Therefore, only serial measurements of LVEF represent the left ventricular contractility or its dynamics.
According to Armstrong et al., 2D echocardiography had a sensitivity of 25% and a false-negative rate of 75% for detection of LVEF < 50% compared with cardiac magnetic resonance imaging [26] . 3D echocardiography provided higher sensitivity (up to 53%), and should be preferred for LVEF measurement. Never- The global longitudinal strain (GLS) is an echocardiographic measure which derives data for deformation and rate of deformation for each of 17 myocardial segments. The decline of GLS by > 15% from the baseline is considered abnormal while the reduction by < 8% from the baseline appears incidental [28] .
GLS is an independent, early predictor of later reduction in LVEF and heart failure [29] . Normal GLS is above 16%, which means that each of the left ventricular segments shortens by at least 16% during systole, as compared to its diastolic length should be discontinued and the patient should be referred to a cardiologist [6] .
Cardiovascular evaluation of patients before and during cancer therapy should be based on the baseline cardiovascular risk profile. In elderly patients with ejection fraction close to the lower reference range or persistent cardiovascular diseases, and in those receiving high doxorubicin equivalent doses, screening should be performed more often and preventive approaches, such as cardioprotective treatment, should be considered [34] .
Concomitant cardiovascular diseases should be monitored and treated during each step of the therapy course.
Anthracyclines may still be used in patients with initially decreased ejection fraction, provided that cardiovascular state is stable and there is an absolute need for anthracycline-based therapy; however, cardioprotective treatment as well as compreEarly diagnostics and prevention of anthracycline-induced cardiomyopathy -the role of cardiologist I.E. Chazova, A.G. Ovchinnikov, F.T. Ageev hensive cardiologic assessment prior to each course of treatment have to be considered. If the decline in EF is > 10% from baseline, accompanied by the absolute value below 30%, the anthracycline-based therapy should be discontinued [35] .
pREvEntIon of AnthRAcyclInE--InducEd cARdIomyopAthy
Poor prognosis of anthracycline-induced heart disease raises the need for preventive approaches. High level of evidence for the prevention of chemotherapy-induced cardiotoxicity was established for iron chelator dexrazoxane, which provided long-term cardioprotection. Historically, the protective role of dexrazoxane was explained by iron chelation that affects anthracycline-induced iron-mediated redox cycling and cytotoxic generation of ROS. However, the ability of dexrazoxane to target topoisomerase 2β and thereby to prevent doxorubicin top2-mediated DNA damaging activities is now considered the main mechanism [38] . A meta-analysis of 10 randomized clinical trials with more than 1600 breast cancer patients has shown that preventive treatment with dexrazoxane reduced the risk of heart failure by 82% [39] . But the concern that dexrazoxane may compromise the anticancer efficacy of anthracyclines limit its approval to patients only with advanced stages of breast cancer who need further anthracycline therapy after having already received 300 mg/m 2 .
Patients with a high risk of anthracycline-induced cardiomyopathy (advanced age, concomitant cardiovascular diseases and decreased ejection fraction) should preferably receive pegylated liposomal doxorubicin instead of usual drug formulation. Liposomal doxorubicin is a system containing high doxorubicin concentration inside a particle enclosed with phospholipid bilayer.
During circulation in plasma, the drug is predominantly sequestered in liposomes. Liposomes are of larger size than free doxorubicin and cross the endothelial barrier of the microcirculatory vessels of normal tissues and organs, including heart, to a lesser extent. Moreover, the prolonged distribution time increases the ability of liposomal doxorubicin to accumulate in tumor where the permeability of endothelium is higher [40] . Polyethylene glycol coating protects liposomes from phagocytosis, which also elongates the presence of doxorubicin in blood and facilitates its accumulation in tumor [41] . The unique pharmacokinetic characteristics of pegylated liposomal doxorubicin resulted in better safety profile together with anticancer efficacy [42] .
For high risk patients of anthracycline-induced cardiomyopathy and for patients with subclinical left ventricular dysfunction (defined by an increased troponin I value or decreased GLS), ACE inhibitors, angiotensin receptor blockers, and β-blockers were shown to effectively prevent the ejection fraction decline and the development of heart failure [43] [44] [45] [46] [47] . Whether β-blockers, ACE inhibitors, or angiotensin receptor blockers are useful in primary prevention is uncertain, although in recent OVERCOM trial, combined treatment with an ACE inhibitor, enalapril, and β-blocker, carvedilol, prevented left-ventricular systolic dysfunction in patients with malignant hemopathies treated with intensive chemotherapy (in 78% of cases with anthracycline) [48] . As for anthracycline-induced cardiomyopathy, there is no specific protocols for management and patients should receive standard therapy for heart failure, including ACE inhibitors (or angiotensin receptor blockers), β-blockers, aldosterone antagonists, diuretics, and glycosides [49, 50] . The subsequent functional monitoring after anthracyclines is important as prompt initiation of heart failure treatment is essential for potent recovery and cardiac event reduction [46, 50] .
KEy notEs
• Prior to cancer treatment, cardiotoxicity risk stratification and clinical screening for underlying or developing cardiovascular diseases are needed, including at least ECG, echocardiography and consultation with a cardiologist.
• Cardioprotective medication with reported benefit for prevention of anthracycline-induced cardiotoxicity should be • Prompt therapy (as required) based on standards of care should be initiated for concomitant cardiovascular diseases.
For elderly patients with concomitant cardiovascular diseases (i.e. those who may benefit from high-dose anthracycline therapy), pegylated liposomal doxorubicin is preferable due to less cardiotoxic effect.
